Fluocinonide


Generic Medicine Info
Indications and Dosage
Topical/Cutaneous
Corticosteroid-responsive dermatoses
Adult: As 0.05% cream/gel/solution/ointment: Apply thinly onto affected area(s) 2-4 times daily depending on the severity of the condition. Reduce dosage once the condition improves. As 0.1% cream: Apply thinly onto affected area(s) once or twice daily. Discontinue when control is achieved; re-evaluate treatment if condition does not improve within 2 weeks.
Child: As 0.05% cream/gel/solution/ointment: >1 year Use the minimum effective dose and limit treatment to 5 days without occlusion. As 0.1% cream: ≥12 years Same as adult dose.
Contraindications
Untreated fungal, tuberculous, viral, or bacterial skin infections; acne, rosacea, perioral dermatitis, anogenital pruritus.
Special Precautions
Patient with psoriasis. Children. Pregnancy and lactation. Avoid contact with eyes and prolonged facial application.
Adverse Reactions
Significant: Hypercortisolism or suppression of hypothalamic-pituitary-adrenal (HPA) axis (especially in children); Kaposi’s sarcoma (prolonged use); allergic contact dermatitis, local application site effects (e.g. skin atrophy, irritation, burning, itching, dryness, telangiectasia, striae, miliaria, perioral dermatitis, folliculitis, acneiform eruptions, hypopigmentation), skin infections; systemic effects (e.g Cushing’s syndrome, hyperglycaemia, glycosuria); growth retardation (prolonged use in children). Rarely, central serous chorioretinopathy.
Skin and subcutaneous tissue disorders: Hypertrichosis, erythema, swelling, pain at application site; skin exfoliation and tightness.
MonitoringParameters
Monitor HPA axis suppression (e.g. ACTH stimulation test, urine free cortisol test); signs of bacterial or fungal infection. Routinely check growth in children (prolonged use).
Drug Interactions
May diminish the antineoplastic effect of aldesleukin.
Action
Description: Fluocinonide is a highly potent fluorinated corticosteroid which has anti-inflammatory, antipruritic, and vasoconstrictive effects. It depresses the formation, release, and action of endogenous chemical mediators of inflammation (e.g. kinins, histamine, liposomal enzymes, prostaglandins) via the induction of phospholipase A2 inhibitory proteins (lipocortins) and sequential inhibition of arachidonic acid release.
Pharmacokinetics:
Absorption: Absorbed percutaneously.
Metabolism: Metabolised mainly in the liver.
Excretion: Via urine and bile.
Chemical Structure

Chemical Structure Image
Fluocinonide

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 9642, Fluocinonide. https://pubchem.ncbi.nlm.nih.gov/compound/Fluocinonide. Accessed Oct. 27, 2020.

Storage
Store between 15-30°C. Protect from excessive heat exposure.
ATC Classification
D07AC08 - fluocinonide ; Belongs to the class of potent (group III) corticosteroids. Used in the treatment of dermatological diseases.
References
Anon. Fluocinonide. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 05/10/2020.

Buckingham R (ed). Fluocinonide. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 05/10/2020.

Fluocinonide Cream, Gel, Ointment 0.5% (Taro Pharmaceuticals U.S.A., Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 23/10/2020.

Fluocinonide Gel 0.05% (Cosette Pharmaceuticals, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 05/10/2020.

Fluocinonide Topical Solution 0.05% (Rising Pharmaceuticals, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 05/10/2020.

Joint Formulary Committee. Fluocinonide. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 05/10/2020.

Lidex 0.05% Ointment (Euro-Med Laboratories Phil., Inc.). MIMS Philippines. http://www.mims.com/philippines. Accessed 23/10/2020.

Metosyn FAPG Cream 0.05% (Reig Jofre UK Limited). MHRA. https://products.mhra.gov.uk/. Accessed 05/10/2020.

Metosyn Ointment 0.05% (Reig Jofre UK Limited). MHRA. https://products.mhra.gov.uk/. Accessed 05/10/2020.

Vanos Cream 0.1% (Valeant Pharmaceuticals North America LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 05/10/2020.

Disclaimer: This information is independently developed by MIMS based on Fluocinonide from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in